Genentech and Roche will put five oral trontinemab presentations into a 90-minute Featured Research Session at AAIC 2026, and the program also includes new Alzheimer’s disease data from the Phase Ib/IIa Brainshuttle AD study. Eli Lilly And Company appears in the conference framing, but the measurable change for researchers is that the discussion now centers on long-term safety, amyloid removal and biomarker readouts, not just a single study update.
18 oral and poster presentations make up the Genentech and Roche AAIC 2026 program, with July 7, 2026 as the announcement date and July 12-15, 2026 as the conference window in London. Levi Garraway, chief medical officer and head of Global Product Development, said the company aims to bring together advanced diagnostics and transformative medicines, with the goal of benefitting many Alzheimer's patients through earlier detection and intervention.
Genentech and Roche AAIC
Five oral presentations will sit inside the trontinemab session, which will feature new long-term safety, amyloid removal and biomarker data from the Phase Ib/IIa Brainshuttle AD open-label extension study. That package matters because the open-label extension is where the earlier signal gets longer follow-up, and it is the only place in this announcement where the therapy’s durability is being paired with the study’s biomarker trail.
Modeling from Brainshuttle AD informed the dosing regimen for the ongoing Phase III TRONTIER 1 and 2 studies in early symptomatic Alzheimer's disease. Genentech and Roche are also set to share the design of PrevenTRON for the first time at AAIC 2026, making the conference the point where the company’s next preclinical Alzheimer's step becomes visible to outside researchers.
Roche Diagnostics and Elecsys pTau217
Roche will use its Elecsys pTau217 blood test to help identify potential PrevenTRON study participants, linking diagnostics to trial enrollment rather than leaving the two efforts separate. Matt Sause, CEO of Roche Diagnostics, said, “With the approval of Elecsys pTau217, our third Alzheimer's blood test, across both primary and secondary care, we are making timely and definitive diagnosis more accessible than ever before.”
He added, “For too long, this has been out of reach for the vast majority of patients.” He also said, “As a result, millions have been left without the answers, care and support they need.”
NLRP3 and the access gap
Matt Sause said, “That is now changing, as blood-based testing transforms the diagnosis of Alzheimer's disease.” Genentech and Roche will also present an invited Perspectives Session on NLRP3 inflammasome in Alzheimer's disease, extending the program beyond trontinemab into neuroinflammatory approaches.
The friction in the story is plain: Roche says blood-based testing is making diagnosis more accessible, while it also says for too long definitive diagnosis has been out of reach for the vast majority of patients. If Elecsys pTau217 can narrow that gap for PrevenTRON screening, then the practical outcome is not just a conference slide deck — it is a tighter path from blood test to study entry to the next Phase III readout in early symptomatic and preclinical AD.
The unanswered piece is the actual long-term safety, amyloid removal and biomarker profile from Brainshuttle AD that will be shown in London. Those data will determine whether the five oral trontinemab presentations read as a progress report or the start of a broader clinical push.
